Cognition Therapeutics Inc CGTX
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-08 |
| Shares Out. | 89,500,000 |
| Website | cogrx.com/ ↗ |
| Phone | 13026974590 |
| Employees | 14 |
| Net Income | -$4.6M |
| Total Assets | $36.1M |
| Total Liabilities | $6.2M |
| Equity | $29.9M |
About Cognition Therapeutics Inc
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Cognition Therapeutics Inc is a publicly traded company under the ticker symbol CGTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)